Friday, September 05 - 2008

Genzyme inaugurates Middle East office in Dubai

Genzyme Corporation, a global biotechnology company, announced today the official opening of its Middle East office based in Dubai, United Arab Emirates.

  • United Arab Emirates: Thursday, November 09 - 2006 at 15:52
  • PRESS RELEASE



sponsored link

related stories
The new office, which will be established at the Dubai Biotechnology and Research Park (DuBiotech), expands Genzyme's global network to improve support for patients and the medical community in that region.

'Genzyme has spent 25 years building its global infrastructure. Establishing a regional base in Dubai, the technological and commercial hub of the Middle East, is an exciting occasion, as it will allow us to better understand and address the specific health care systems and business environments of the area,'



said Sandford Smith, Genzyme President, International Group.

The Dubai office will provide regional sales and marketing support to customers and distributors for its enzyme replacement treatments for Gaucher, MPS I, Fabry and Pompe, four Lysosomal Storage Diseases*. It will also support activities for Renagel, a treatment to reduce the phosphorus levels in chronic kidney disease patients on hemodialysis, Thymoglobulin, an immunosuppressant for treating and preventing acute rejection in renal transplant patients, and Thyrogen, an adjunct to thyroid cancer disease management designed to aid in the treatment and earlier detection of recurrence.

Sheikh Khalifa Medical City in Abu Dhabi, UAE, was the first clinic in the Middle East to treat a Pompe patient with Genzyme's newly approved enzyme replacement therapy Myozyme®. In September, Myozyme earned the 2006 UK Prix Galien Gold Medal, a prestigious international award that honours outstanding achievement in pharmaceutical research and development in the United Kingdom.

'We are delighted to welcome Genzyme, the latest global company to join the DuBiotech community,' said Dr. Abdulqader Al Khayat, Executive Director of DuBiotech. 'Partnering with industry leaders like Genzyme will help build the region's biotechnology industry. Genzyme's presence will add considerable value to the DuBiotech community.'

Genzyme in the Middle East

The Dubai office will represent Genzyme in Bahrain, Egypt, Iran, Iraq, Jordan, Kuwait, Lebanon, Libya, Malta, the Sultanate of Oman, the Kingdom of Saudi Arabia, the United Arab Emirates and Qatar. Further activities in Yemen, Syria and Sudan could be foreseen.

Initially, three full-time employees will be working out of the Dubai office, in addition to sales representatives in Egypt and Saudi Arabia. Genzyme also anticipates adding staff for administrative, regulatory and customer service functions in the coming years. Ariaan Schipper will continue to serve as Genzyme's Regional Director for the Middle East from the Dubai office. 'We are looking forward to expanding our services in the area so we can build a closer relationship with our stakeholders and so more patients with serious medical needs can benefit from our specialised therapies,' said Schipper.




request information Log in to request more information from DuBiotech

Notes and media contacts

About Genzyme
One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. This year marks the 25th anniversary of Genzyme's founding. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 8,500 employees in locations spanning the globe and 2005 revenues of $2.7 billion. Genzyme has been selected by FORTUNE as one of the '100 Best Companies to Work for' in the United States. With many established products and services helping patients in more than 80 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant and immune diseases, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as heart disease and other areas of unmet medical need.

For more information about Genzyme, please consult www.genzyme.com.

About DuBiotech

The Dubai Biotechnology and Research Park (DuBiotech), launched in February 2005, is the region's first and foremost science and Business Park dedicated entirely to the global life science industry. DuBiotech aims to be the central hub for all life science industries for the greater Middle East. DuBiotech offers a vibrant environment for key players of such industries to thrive. The park offers drug manufacturers and industry specific service providers all the support needed to make their presence at DuBiotech an efficient and effective process. Such service providers include suppliers of laboratory equipment and reagents, venture capital firms, design consultants, etc. Apart from the headquarters and its state-of-the-art laboratory complexes, DuBiotech additionally offers a unique environment where companies can truly capture and serve their target market in a setting that reflects DuBiotech's dedication to exceptional architecture and practicality with an emphasis towards the requirements of life science companies. A central focus of DuBiotech is research, and to support the drive toward setting a park dedicated to research excellence, DuBiotech has established the Foundation for Research and Innovation (FRI). The FRI will initially focus on medical, industrial, environmental and agricultural biotechnology. DuBiotech is governed by world class regulations in line with those applied to the top life science clusters globally. By working closely with the industry, federal authorities and world IP bodies, DuBiotech will ensure that existing IP laws and regulations are strictly enforced. DuBiotech attaches considerable importance to Intellectual Property issues, considering the sensitive nature of work done within this industry. As part of TECOM's corporate social responsibility, all DuBiotech's buildings are to be classified as LEED certified 'Green' buildings.

For further information about DuBiotech:
Baiju Francis
Account Manager
JIWIN, The Public Relations Arm of Dubai Press Club
T:+9714 361 3 596
F:+9714 368 8 001
M:+97150 7971996
Anne-Birte Stensgaard Posted by Anne-Birte Stensgaard, Senior News Editor
Thursday, November 09 - 2006 at 15:52 UAE local time (GMT+4)

Replication or redistribution in whole or in part is expressly prohibited without the prior written consent of AME Info FZ LLC / Emap Limited.

This Article was updated on Saturday, November 11 - 2006
Disclaimer:
Articles in this section are primarily provided directly by the companies appearing or PR agencies which are solely responsible for the content. The companies concerned may use the above content on their respective web sites provided they link back to http://www.ameinfo.com

Any opinions, advice, statements, offers or other information expressed in this section of the AME Info Web site are those of the authors and do not necessarily reflect the views of AME Info FZ LLC / Emap Limited. AME Info FZ LLC / Emap Limited is not responsible or liable for the content, accuracy or reliability of any material, advice, opinion or statement in this section of the AME Info Web site.

For details about submitting your stories, please read the guide - all content published is subject to our terms and conditions

Sponsored Links

Business Directory »

The news you choose

News and Articles »

Current Events »

Advertisement »